Mar 06, 2023 8:05am EST Dr. Lynn Kirkpatrick, Featured Speaker to Discuss Ensysce Overdose Protection Platform at DCAT Seminar
Feb 28, 2023 8:05am EST Ensysce Biosciences Announces Critical Step in Human Abuse Potential Study of PF614 With Database Lock
Feb 14, 2023 8:00am EST Ensysce Biosciences to Present its Overdose Protection Program at the 4th Annual NIH 'HELPING END ADDICTION LONG-TERM' (HEAL) Meeting
Feb 07, 2023 8:05am EST Ensysce Biosciences, Inc. Announces Closing of $3.0 Million Registered Direct Offering Priced at-the-Market Under NASDAQ Rules
Feb 01, 2023 8:05am EST Ensysce Biosciences Announces the Distribution of Series A Preferred Stock to Holders of Its Common Stock
Jan 25, 2023 8:05am EST Ensysce Biosciences Announces Initiation of Final Stage of Groundbreaking Opioid Overdose Protection Phase 1 Study
Jan 23, 2023 8:05am EST Ensysce Biosciences to Present at Diamond Equity Research 2023 Virtual Emerging Growth Invitational